PT - JOURNAL ARTICLE AU - Müller, Michael AU - Volzke, Johann AU - Subin, Behnam AU - Schmidt, Christian J. AU - Geerdes-Fenge, Hilte AU - Reisinger, Emil C. AU - Müller-Hilke, Brigitte TI - Distinguishing Incubation and Acute Disease Stages of Mild-to-Moderate COVID-19 AID - 10.1101/2021.09.07.21263200 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.07.21263200 4099 - http://medrxiv.org/content/early/2021/09/13/2021.09.07.21263200.short 4100 - http://medrxiv.org/content/early/2021/09/13/2021.09.07.21263200.full AB - Objective While numerous studies have already compared the immune responses against SARS-CoV-2 in severely and mild-to-moderately ill COVID-19 patients, longitudinal trajectories are still scarce. We therefore set out to analyze serial blood samples from mild-to-moderately ill patients in order to define the immune landscapes for differently progressed disease stages.Methods Twenty-two COVID-19 patients were subjected to consecutive venipuncture within seven days after diagnosis or admittance to hospital. Flow cytometry was performed to analyze peripheral blood immune cell compositions and their activation as were plasma levels of cytokines and SARS-CoV-2 specific immunoglobulins. Healthy donors served as controls.Results Integrating the kinetics of plasmablasts and SARS-CoV-2 specific antibodies allowed for the definition of three disease stages of early COVID-19. The incubation phase was characterized by a sharp increase in pro-inflammatory monocytes and terminally differentiated cytotoxic T cells. The latter correlated significantly with elevated concentrations of IP-10. Early acute infection featured a peak in PD-1+ cytotoxic T cells, plasmablasts and increasing titers of virus specific antibodies. During late acute infection, immature neutrophils were enriched whereas all other parameters returned to baseline.Conclusion Our findings will help to define landmarks that are indispensable for the refinement of new anti-viral and anti-inflammatory therapeutics, and may also inform clinicians to optimize treatment and prevent fatal outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was financially supported by the Federal State of Mecklenburg-Western Pomerania via the Sondervermoegen des MV Schutzfonds Saeule Gesundheit.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies involving human participants were reviewed and approved by the ethics committee of the University Medical Center of Rostock (reference number A 2020-0086). Written informed consent was obtained from all study participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article (and its supplementary information files).